Source: AJP-Renal physiology. Unidade: FM
Subjects: MAGNÉSIO (DEFICIÊNCIA), EXCREÇÃO, FÁRMACOS IMUNOSSUPRESSORES, CÁLCIO (DEFICIÊNCIA)
ABNT
ALEXANDRE, Cristianne da Silva et al. Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and dowregulation of NKCC2 protein expression. AJP-Renal physiology, v. 297, n. 4, p. 922-926, 2009Tradução . . Disponível em: https://doi.org/10.1152/ajprenal.90256.2008. Acesso em: 02 out. 2024.APA
Alexandre, C. da S., Bragança, A. C. de, Shimizu, M. H. M., Sanches, T. R., Fortes, M. A. Z., Giorgi, R. R., et al. (2009). Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and dowregulation of NKCC2 protein expression. AJP-Renal physiology, 297( 4), 922-926. doi:10.1152/ajprenal.90256.2008NLM
Alexandre C da S, Bragança AC de, Shimizu MHM, Sanches TR, Fortes MAZ, Giorgi RR, Andrade L da C, Seguro AC. Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and dowregulation of NKCC2 protein expression [Internet]. AJP-Renal physiology. 2009 ; 297( 4): 922-926.[citado 2024 out. 02 ] Available from: https://doi.org/10.1152/ajprenal.90256.2008Vancouver
Alexandre C da S, Bragança AC de, Shimizu MHM, Sanches TR, Fortes MAZ, Giorgi RR, Andrade L da C, Seguro AC. Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and dowregulation of NKCC2 protein expression [Internet]. AJP-Renal physiology. 2009 ; 297( 4): 922-926.[citado 2024 out. 02 ] Available from: https://doi.org/10.1152/ajprenal.90256.2008